Showing 117 of 117on this page. Filters & sort apply to loaded results; URL updates for sharing.117 of 117 on this page
ESMO 22: Results of the 177Lu-PNT2002 SPLASH Trial | GU Oncology Now
PNT2002 / POINT Biopharma, Lantheus
Lutetium-177 PNT2002 for Prostate Cancer | Open Medscience
Anticipated Timelines PNT2002 (Prostate Cancer) PNT2003 (SSRT+ non-GEP ...
ESMO 2024: Invited Discussant: Efficacy of SPLASH and UpFrontPSMA Trials
Point looks to make a year-end Splash | ApexOnco - Clinical Trials news ...
PnT2002 · player info | osu!
Point’s big Splash falls short | ApexOnco - Clinical Trials news and ...
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following ...
Frontiers | Initial clinical experience with [177Lu]Lu-PNT2002 ...
ASCO 2021: Study Evaluating Metastatic Castrate Resistant Prostate ...
Clinical Trials of New Therapies for Advanced Prostate Cancer | ZERO ...
ESMO 2022: Efficacy and Safety of 177Lu-PNT2002 Prostate-Specific ...
SPLASH: 177Lu-PNT2002 achieves phase 3 outcomes for mCRPC
177Lu-PNT2002 Received FDA Fast Track Designation for Metastatic CRPC
POINT生物制药在PNT2002的3期SPLASH试验中完成随机化 - 中国核技术网
SPLASH: 177Lu-PNT2002 achieves phase 3 outcomes for mCRPC | Urology Times
Lantheus' 177Lu-PNT2002 Shows Promise in mCRPC Treatment: Phase 3 ...
1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane ...
FDA Fast Tracks 177Lu-PNT2002 for the Treatment of mCRPC
【速递】礼来收购PSMA核药变故？从市场竞争角度分析医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Novel Treatment Targets in the Metastatic Castrate-Resistant Prostate ...
177Lu-PNT2002 Significantly Improves rPFS Vs ARPI in Metastatic ...
177Lu-PNT2002 Boosts rPFS in PSMA+ mCRPC Following ARPI Progression
Dose‐adapted stereotactic body radiation therapy based on the response ...
核药赛道探险者：POINT Biopharma，扎根高端用药布局_摩熵医药(原药融云)
PSMA-Targeting Radioligand Therapy in Prostate Cancer | Published in ...
LBA65 Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following ...
FDA Fast Tracks 177Lu-PNT2002 for the Treatment of mCRPC | Targeted ...
ESMO 2024: Scientific Congress Highlights: Genitourinary Tumors, Prostate
Prostate Cancer Molecular Imaging and Therapy in MIRROR and 177Lu ...
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company on ...
Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following Progression ...
Abstract PO-077: Study evaluating metastatic castrate resistant ...
First European Union Patient Dosed With 177Lu-PNT2002 in the Phase 3 ...
177Lu-PNT2002 Meets Primary Endpoint in Phase III mCRPC Trial ...
ESMO24 - 177Lu-PNT2002 bemoedigend na progressie op AR-pathwayremmer ...
Beyond a VISION to Making a SPLASH: Advances in PSMA-Based Theranostics ...
Lantheus和POINT 生物制药宣布就PNT2002和PNT2003的商业化达成战略合作和独家许可协议 - 中国核技术网
Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate ...
Michael Gottlieb on LinkedIn: #prostatecancer
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation ...
Study on Treating Metastatic Castration-Resistant Prostate Cancer with ...
超20亿美元！Lantheus引进两款3期临床放射性药物全球独家权益医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
[Lu-177]-PNT2002 for Prostate Cancer Clinical Trial 2023 | Power
Lantheus and POINT Biopharma Announce Positive Topline Results from ...
slide1
從PSMAfore與SPLASH試驗成果探索放射性製藥業的核心能力 – 台灣核醫診療標靶治療之友協會
Revolution of Radiopharmaceuticals: From Diagnosis to Treatment
Lantheus Entered into an Exclusive License Agreements with POINT ...
Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy ...
#esmo24 #gu #splash #mcrpc #prostatecancer #esmo24 #oncology ...
slide53
:%0A%0A[Lu-177]-PNT2002%20for%20Prostate%20Cancer.png?md=1)
